/ALVR
ALVR Stock - AlloVir, Inc.
Healthcare|BiotechnologyNASDAQ
$9.81+4.14%
+$0.39 (+4.14%) • Mar 18
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $10.79
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALVR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.71 – $9.91
TARGET (TP)$11.28
STOP LOSS$9.03
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$24.15
52W Low$7.96
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-398,000 | $-2,565,000 | $-1,117,000 | $-73,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-65,441,000 | $-181,331,000 | $-171,202,000 | $-169,818,000 | $-71,309,000 |
| Net Income | $-58,769,000 | $-190,418,000 | $-168,710,000 | $-171,962,000 | $-69,784,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-11.73 | $-42.09 | $-50.60 | $-63.02 | $-59.57 |
Company Overview
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
1
33%
Sell / Underperform
1
33%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$9
Average Target
↓ 8.3% Downside
Now
$1
Low
$9
Average
$17
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 26th 2023 | BofA Securities | Downgrade | Underperform | $1← $17 |
| December 22nd 2023 | Leerink Partners | Downgrade | Market Perform | - |
| December 22nd 2023 | Piper Sandler | Downgrade | Neutral | - |
| December 22nd 2023 | JP Morgan | Downgrade | Underweight | - |
| August 18th 2023 | BofA Securities | Initiation | Buy | $17 |
Earnings History & Surprises
ALVRBeat Rate
59%
Last 17 quarters
Avg Surprise
+8.1%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-0.64
Q4 2025
EPS Surprise History
Q4 23
+7.1%
$-8.97vs$-9.66
Q1 24
-23.2%
$-12.18vs$-9.89
Q2 24
-12.5%
$-4.14vs$-3.68
Q3 24
+50.0%
$-1.15vs$-2.30
Q4 24
+71.4%
$-0.92vs$-3.22
Q1 25
+94.3%
$-0.16vs$-2.76
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | $-0.64 | — | — |
Q3 2025 | Aug 7, 2025 | — | $-0.61 | — | — |
Q2 2025 | May 12, 2025 | — | — | — | — |
Q1 2025 | Mar 7, 2025 | $-2.76 | $-0.16 | +94.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-3.22 | $-0.92 | +71.4% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-2.30 | $-1.15 | +50.0% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-3.68 | $-4.14 | -12.5% | ✗ MISS |
Q1 2024 | Mar 15, 2024 | $-9.89 | $-12.18 | -23.2% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-9.66 | $-8.97 | +7.1% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-10.34 | $-11.03 | -6.7% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-10.80 | $-10.11 | +6.4% | ✓ BEAT |
Q1 2023 | Feb 15, 2023 | $-11.72 | $-8.51 | +27.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-11.95 | $-11.49 | +3.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-16.09 | $-15.86 | +1.4% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-17.01 | $-15.86 | +6.8% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $-16.32 | $-21.15 | -29.6% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-13.56 | $-16.55 | -22.1% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-10.57 | $-13.79 | -30.5% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-9.20 | $-11.49 | -24.9% | ✗ MISS |
Q1 2021 | Feb 11, 2021 | $-0.42 | $-0.34 | +19.0% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ALVR
What is ALVR's current stock price?
AlloVir, Inc. (ALVR) is currently trading at $9.81 per share. The stock has moved +4.14% today.
What is the analyst price target for ALVR?
No analyst price targets are currently available for this stock.
What sector is AlloVir, Inc. in?
AlloVir, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALVR's market cap?
AlloVir, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does ALVR pay dividends?
No, AlloVir, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHL
Achilles Therapeutics plc
$1.48
Mkt Cap: $0.1B
BLUE
bluebird bio, Inc.
$4.97
Mkt Cap: $0.0B
GRNA
GreenLight Biosciences Holdings
$0.30
Mkt Cap: $0.0B
KRON
Kronos Bio, Inc.
$0.88
Mkt Cap: $0.1B
MGTA
Magenta Therapeutics, Inc.
$0.70
Mkt Cap: $0.0B
PSTI
Pluristem Therapeutics Inc.
$1.00
Mkt Cap: $0.0B
RENB
Lunai Bioworks Inc.
$1.42
Mkt Cap: $0.0B
RNTX
Rein Therapeutics Inc.
$1.42
Mkt Cap: $0.0B
SGTX
Sigilon Therapeutics, Inc.
$22.47
Mkt Cap: $0.1B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
Explore stocks similar to ALVR for comparison